11-Phenyl-[b,e]-dibenzazepine compounds: Novel antitumor agents

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 1, 2009, Pages 104-107

  Al Qawasmeh, Raed A ^a   Lee, Yoon ^b   Cao, Ming Yu ^b   Gu, Xiaoping ^b   Viau, Stéphane ^b   Lightfoot, Jeff ^b   Wright, Jim A ^b   Young, Aiping H ^b  

^a UNIVERSITY OF JORDAN   (Jordan)

^b Lorus Therapeutics Inc   (Canada)

Author keywords

Antitumor; Cell cycle; Clotrimazole; Dibenzazepines; Heterocycles

Indexed keywords

11 PHENYL[B,E]DIBENZAZEPINE DERIVATIVE; ANTINEOPLASTIC AGENT; CLOTRIMAZOLE; DIBENZAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIBENZAZEPINES; DRUG SCREENING ASSAYS, ANTITUMOR; G0 PHASE; G1 PHASE; HUMANS; INHIBITORY CONCENTRATION 50; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 57749086838     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.11.001     Document Type: Article

References (21)

1. Ashby J., and Elliott B.M. In: Katritzky A.R., Rees C.W., and Meth-Cohn O. (Eds). Comprehensive Heterocyclic Chemistry Vol. 1 (1984), Pergamon Press, Oxford 111-183
2. Pozharskii A.F., Soldatenkov A.T., and Katritzky A.R. Heterocycles in Life and Society (1997), John Wiley & Sons, New York
3. Liegeois J.F.F., Rogister F.A., Bruhwyler J., Damas J., Nguyen T.P., Inarejos M.O., Chleide E.M.G., Mercier M.G.A., and Delarge J.E. J. Med. Chem. 37 (1994) 519
4. Mlache Y., Hichour M., Blasi G.D., Chezal J.-M., Viols H., Chavignon O., Teulade J.-C., and Chapat J.-P. Heterocycles 51 (1999) 1003 and references therein
5. Heinisch G., Huber E., Matuszczak B., and Mereiter K. Heterocycles 51 (1999) 1035 and references therein
6. Link A., and Kunick C. J. Med. Chem. 41 (1998) 1299
7. Grunewald G.L., Galdwell T.M., Li Q., and Criscione K.R. J. Med. Chem. 44 (2001) 2849
8. Kling A., Backfish G., Delzer J., Geneste H., Graef C., Holzenkamp U., Hornberger W., Lange U.E.W., Lauterbach A., Mack H., Seitz W., and Subkowski T. Bioorg. Med. Chem. Lett. 12 (2002) 441
9. Andrés J.I., Alonso J.M., Fernández J., Iturrino L., Marti'nez P., Meert T.F., and Sipido V.K. Bioorg. Med. Chem. Lett. 12 (2002) 3573
10. Li R., Tränkle C., Mohr K., and Holzgrabe U. Arch. Pharm. 334 (2001) 121
11. Al-Qawasmeh R.A., Lee Y., Cao M.-Y., Gu X., Vassilakos A., Wright J.A., and Young A. Bioorg. Med. Chem. Lett. 14 (2004) 347
12. Cao M.-Y., Lee Y., Feng N.P., Al-Qawasmeh R.A., Viau S., Gu X.P., Lau L., Jin H., Wang M., Vassilakos A., Wright J.A., and Young A.H. J. Pharmacol. Exp. Ther. 308 (2004) 538
13. Benzaquen L.R., Brugnara C., Byers H.R., Gattoni-Celli S., and Halperin J.A. Nat. Med. 1 (1995) 534
14. Aktas H., Fluckiger R., Acosta J.A., Savage J.M., Palakurthi S.S., and Halperin J.A. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8280
15. Sasakura K., and Sugasawa T. Heterocycles 15 (1981) 421
16. Sugasawa T., Toyoda T., Adachi M., and Sasakura K.J. Am. Chem. Soc. 100 (1978) 4842
17. 3) 7.62 (bd, 1H), 7.48 (bd, 1H), 7.32-7.04 (m, 8H), 6.68 (bt, 1H), 6.58 (bd, 1H), 5.36 (bs,1H), 4.64 (d,1H), 4.25 (bs,1H), 3.65 (bd,1H).
18. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., and Boyd M.R. Cancer Res. 48 (1988) 589
19. Based on the results of the 60-cell line assay performed by NCI, these three compounds have been referred to the biological committee in order to study their spectrum of activity as compounds with novel activity. This resulted in a recommendation by the NCI to further evaluate these compounds in preclinical stages.
20. http://dtp.nci.nih.gov/docs/compare/compare.html.
21. Cell cycle analysis: H460 and HT-29 cells were cultured in complete medium containing 0.1%DMSO, 10, 25, and 50 μM 9. Cells were harvested 16 h following treatment, and washed with cold PBS twice. Cells were fixed in 70% ethanol at 4 °C at least 4 h. The fixed cells were centrifuged at 1500 rpm for 4 min at 4 °C, washed with cold PBS containing 2% FBS twice, treated with 3 mg/ml ribonuclease (Sigma Chemical Co) and 50 μg/ml propidium iodide (PI) (Sigma Chemical Co) for 30 min at 37 °C. Flow cytometry analysis was performed on the Becton Dickinson fluorescence-activated sorter FACS Scan by using the Becton Dickinson Cell Quest program. Data were evaluated using Modfit software (Verity Software House, Topsham, ME).